Annovis Bio, Inc.
ANVSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Annovis Bio, Inc. focuses on Biotechnology services and products. Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. With a market capitalization of $74.4M, it sits in micro-cap territory. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Market Cap
$74.4M
Beta
1.19
P/E (TTM)
—
P/E (Fwd)
-1.98
EPS (TTM)
$-1.77
EPS (Fwd)
$-0.89
ROE
-301.1%
ROA
-120.2%
Cash
$14.2M
Total Debt
$0
Free CF
-$11.6M
52W Change
-31.9%
Annual Financials
Cash vs Debt
Where ANVS stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ANVS finished 31.33% below its 150-day moving average ($2.49) and 32.41% below its 200-day moving average ($2.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANVS overbought or oversold?
At the July 15, 2026 close, ANVS's RSI(14) was 48.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Annovis Bio, Inc. reports $14.2M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$11.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -301.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Annovis Bio, Inc.'s trajectory.